News
Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli
Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating their protein-based vaccine technology. The approval positions Novavax as the only non-mRNA COVID-19 vaccine with full FDA approval, offering a differentiated alternative amid growing mRNA fatigue.
A panel of advisers to the U.S. Food and Drug Administration (FDA) has recommended that for the upcoming fall and winter immunization campaigns, COVID-19 vaccine makers should formulate their shots to ...
Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after BioMarin BMRN agreed to acquire Inozyme Pharma INZY. Meanwhile, other pipeline and ...
BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. (NASDAQ:NVAX) stock, setting a price target of $10. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback